Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-trifluoromethyl-n-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1h)-yl)-benzamide
2. Benzamide, N-((3ar,4r,4ar,5as,6s,6as)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1h)-yl)-4-(trifluoromethyl)-, Hydrate (1:1), Rel-
3. N-((3ar,4r,4ar,5as,6s,6as)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa(f)isoindol-2(1h)-yl)-4-(trifluoromethyl)benzamide
4. Siga-246
5. St 246
6. St-246
7. Tecovirimat Monohydrate
8. Tpoxx
1. 869572-92-9
2. Siga-246
3. St 246
4. Tpoxx
5. St-246
6. F925rr824r
7. 816458-31-8
8. N-(3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl)-4-(trifluoromethyl)benzamide
9. N-[(1r,2r,6s,7s,8s,10r)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide
10. Benzamide, N-((3ar,4r,4ar,5as,6s,6as)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1h)-yl)-4-(trifluoromethyl)-, Rel-
11. Tecovirimat [usan]
12. Tecovirimat [usan:inn]
13. Unii-f925rr824r
14. Siga 246
15. 4-trifluoromethyl-n-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1h)-yl)-benzamide
16. Benzamide, N-[(3ar,4r,4ar,5as,6s,6as)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1h)-yl]-4-(trifluoromethyl)-, Rel-
17. N-((3ar,4r,4ar,5as,6s,6as)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa(f)isoindol-2(1h)-yl)-4-(trifluoromethyl)benzamide
18. Tecovirimat [mi]
19. Tecovirimat [inn]
20. Tecovirimat [who-dd]
21. Schembl404743
22. Arestvyr;iga-246;t-246
23. Chembl1257073
24. Schembl21670085
25. Tecovirimat [orange Book]
26. Dtxsid101026474
27. Ex-a4340
28. Bdbm50577060
29. S3380
30. St-246st-246
31. Zinc35323125
32. Akos030260536
33. Cs-3464
34. Db12020
35. Hy-14805
36. N-(dioxo[?]yl)-4-(trifluoromethyl)benzamide
37. 458t318
38. Q7692792
39. N-[(3ar,4r,4ar,5as,6s,6as)-1,3-dioxooctahydro-4,6-ethenocyclopropa[f]isoindol-2(1h)-yl]-4-(trifluoromethyl)benzamide
| Molecular Weight | 376.3 g/mol |
|---|---|
| Molecular Formula | C19H15F3N2O3 |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 1 |
| Exact Mass | 376.10347683 g/mol |
| Monoisotopic Mass | 376.10347683 g/mol |
| Topological Polar Surface Area | 66.5 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 705 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Tecovirimat is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 13 kg. The efficacy of tecovirimat may be reduced in immunocompromised patients.
FDA Label
Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:
- Smallpox
- Monkeypox
- Cowpox
Tecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 and 5. 1).
Tecovirimat SIGA should be used in accordance with official recommendations.
Tecovirimat prevents viral spread throughout the body. This drug inhibits its molecular target, a protein called p37, from interacting with intracellular transport components necessary for the production of enveloped virus, and therefore the spread of virus.
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
J05AX24
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AX - Other antivirals
J05AX24 - Tecovirimat
Absorption
Readily absorbed following oral administration, with mean times to maximum concentration from 3 to 4 h. A study was conducted to determine the safety, tolerability, and pharmacokinetics of ST-246 administered as a single daily oral dose. Steady state was reached by day 6 (within 3 to 5 half-lives).
Route of Elimination
Less than 0.02% of the drug is excreted unchanged in the kidney, with a majority of the drug being excreted in glucuronidated form. Approximately 23% of unchanged drug is found in the feces.
Volume of Distribution
Approximately 1,356 L. Following oral administration in mice, [14C]-tecovirimat was distributed to all tissues analyzed with the highest concentrations noted in liver and gallbladder, respiratory tract tissues (i.e., nasal turbinates), and bone marrow. Studies in dogs and NHPs suggest that tecovirimat crosses the blood-brain barrier.
Clearance
Mainly renal.
In vitro studies indicate that tecovirimat is not a substrate of major cytochrome P450 (CYP) enzymes, but it is a substrate of human recombinant UGTs (specifically of UGT1A1 and 1A4). Tecovirimat was found to be metabolized into 3 most abundant metabolites, M4, M5 and TFMBA, which do not have pharmacological activity.
Approximately 20h.
Tecovirimat inhibits the production of extracellular viral forms, which are responsible for the systemic spread of infection, inhibiting virus-induced cytopathic effects. Tecovirimat does not inhibit the formation of intracellular forms of the virus (IMV); however, by inhibiting envelopment, and therefore preventing the exit of viral particles from an infected cell, the smallpox infection is slowed to a point where the immune system can eliminate the virus. Tecovirimat has shown a high level of selectivity and specificity for orthopoxviruses. Tecovirimat targets the viral p37 protein, a highly conserved protein with no homologs outside of the Orthopoxvirus genus, inhibiting its function that is necessary for required for the viral envelopment of IMV (intracellular mature virus). Tecovirimat interferes with the cellular localization of p37 viral protein and prevents its association with cellular proteins involved in membrane trafficking.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
The agreement aims for the procurement of Tpoxx (tecovirimat), an antiviral, approved in the US and Canada for the treatment of smallpox and authorized in EU and the UK for smallpox, mpox and cowpox.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Brand Name: Tpoxx
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: U.S. Department of Defense
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 21, 2024
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : U.S. Department of Defense
Deal Size : Undisclosed
Deal Type : Agreement
SIGA Awarded $9M U.S. Defense Contract For TPOXX Procurement
Details : The agreement aims for the procurement of Tpoxx (tecovirimat), an antiviral, approved in the US and Canada for the treatment of smallpox and authorized in EU and the UK for smallpox, mpox and cowpox.
Brand Name : Tpoxx
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 21, 2024
Details:
Tpoxx (tecovirimat) is an oral orthopoxvirus VP37 envelope-wrapping protein inhibitor, Currently, it is being evaluated in the mid-stage clinical trial for the treatment of Monkeypox Virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Brand Name: Tpoxx
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2024
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released
Details : Tpoxx (tecovirimat) is an oral orthopoxvirus VP37 envelope-wrapping protein inhibitor, Currently, it is being evaluated in the mid-stage clinical trial for the treatment of Monkeypox Virus.
Brand Name : Tpoxx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2024
Details:
The agreement aims to expand access to Tpoxx (tecovirimat), a novel small-molecule drug for the treatment of smallpox, to the member states in the ASEAN.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Brand Name: Tpoxx
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: ASEAN
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment June 17, 2024
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : ASEAN
Deal Size : Undisclosed
Deal Type : Divestment
SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
Details : The agreement aims to expand access to Tpoxx (tecovirimat), a novel small-molecule drug for the treatment of smallpox, to the member states in the ASEAN.
Brand Name : Tpoxx
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 17, 2024
Details:
SIGA will lead international promotions for oral TPOXX, an FDA-approved drug for smallpox, while maintaining its contractual relationship with Meridian to ensure continuity for key customers.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Brand Name: Tpoxx
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: SIGA Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2024
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : SIGA Technologies
Deal Size : Undisclosed
Deal Type : Agreement
SIGA Amends International Agreement for Oral TPOXX® Growth
Details : SIGA will lead international promotions for oral TPOXX, an FDA-approved drug for smallpox, while maintaining its contractual relationship with Meridian to ensure continuity for key customers.
Brand Name : Tpoxx
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 01, 2024
Details:
TPOXX (tecovirimat), also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Brand Name: Tpoxx
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Tr...
Details : TPOXX (tecovirimat), also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
Brand Name : Tpoxx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2022
Details:
Tecovirimat (also known as TPOXX®) prevents the virus from leaving infected cells, stopping its spread within the body for monkeypox based on promising results from initial studies in animals and evidence of safety in healthy human volunteers.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Brand Name: Tpoxx
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
New Clinical Trial to Test Treatment for Monkeypox
Details : Tecovirimat (also known as TPOXX®) prevents the virus from leaving infected cells, stopping its spread within the body for monkeypox based on promising results from initial studies in animals and evidence of safety in healthy human volunteers.
Brand Name : Tpoxx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 23, 2022
Details:
The Company has also demonstrated the ability of NV-387 to encapsulate and improve the pharmacokinetics and pharmacodynamics of a very difficult drug, namely remdesivir, that is formulated in a cyclodextrin-based formulation at present (Veklury® Gilead).
Lead Product(s): Tecovirimat,NV-387
Therapeutic Area: Infections and Infectious Diseases Brand Name: NV-387
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Lead Product(s) : Tecovirimat,NV-387
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus
Details : The Company has also demonstrated the ability of NV-387 to encapsulate and improve the pharmacokinetics and pharmacodynamics of a very difficult drug, namely remdesivir, that is formulated in a cyclodextrin-based formulation at present (Veklury® Gilead)...
Brand Name : NV-387
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 04, 2022
Details:
TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors, there is also the potential it could increase immunotherapeutic outcomes.
Lead Product(s): Vaccinia-based Cancer Therapy,Tecovirimat
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: KaliVir Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 15, 2022
Lead Product(s) : Vaccinia-based Cancer Therapy,Tecovirimat
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : KaliVir Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
Details : TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors, there is also the potential it could increase immunotherapeutic outcomes.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 15, 2022
Details:
TPOXX (tecovirimat, ST-246®), a novel small-molecule drug, is an orthopoxvirus VP37 envelope wrapping protein inhibits the viral maturation of variola virus and other poxviruses by preventing the formation of a secondary viral envelope.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Brand Name: Tpoxx
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Catalent Pharma Solutions
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Catalent Pharma Solutions
Deal Size : Not Applicable
Deal Type : Not Applicable
SIGA Technologies Receives Approval from UK for Tecovirimat
Details : TPOXX (tecovirimat, ST-246®), a novel small-molecule drug, is an orthopoxvirus VP37 envelope wrapping protein inhibits the viral maturation of variola virus and other poxviruses by preventing the formation of a secondary viral envelope.
Brand Name : Tpoxx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 08, 2022
Details:
TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Brand Name: Tpoxx
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Patheon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Patheon
Deal Size : Not Applicable
Deal Type : Not Applicable
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
Details : TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX und...
Brand Name : Tpoxx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Tecovirimat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tecovirimat, including repackagers and relabelers. The FDA regulates Tecovirimat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tecovirimat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tecovirimat supplier is an individual or a company that provides Tecovirimat active pharmaceutical ingredient (API) or Tecovirimat finished formulations upon request. The Tecovirimat suppliers may include Tecovirimat API manufacturers, exporters, distributors and traders.
click here to find a list of Tecovirimat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tecovirimat DMF (Drug Master File) is a document detailing the whole manufacturing process of Tecovirimat active pharmaceutical ingredient (API) in detail. Different forms of Tecovirimat DMFs exist exist since differing nations have different regulations, such as Tecovirimat USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tecovirimat DMF submitted to regulatory agencies in the US is known as a USDMF. Tecovirimat USDMF includes data on Tecovirimat's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tecovirimat USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tecovirimat suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tecovirimat as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tecovirimat API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tecovirimat as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tecovirimat and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tecovirimat NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tecovirimat suppliers with NDC on PharmaCompass.
Tecovirimat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tecovirimat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tecovirimat GMP manufacturer or Tecovirimat GMP API supplier for your needs.
A Tecovirimat CoA (Certificate of Analysis) is a formal document that attests to Tecovirimat's compliance with Tecovirimat specifications and serves as a tool for batch-level quality control.
Tecovirimat CoA mostly includes findings from lab analyses of a specific batch. For each Tecovirimat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tecovirimat may be tested according to a variety of international standards, such as European Pharmacopoeia (Tecovirimat EP), Tecovirimat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tecovirimat USP).
LOOKING FOR A SUPPLIER?
